PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO PRABE

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

10/681,049

Filting Date

Coctober 07, 2003

First Named Inventor

Group Art Unit

1621

Examiner Name

Brian J. Davis

Sheet 1 of 15 Attorney Docket Number HDAC-5002-U

			U.S. PATENT	OCUMENTS	
Examiner	Cite	Document Number	Publication Date/	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
Initials *	No.	Number - Kind Cods ² (if known)	Issue Date MM-DD-YYYY		Passages or Relevant Figures Appear
ROD	AA	US 4,482,571	11/13/1984	Abraham Donald J.	
	AB	US 4,997,815	3/5/1991	Perrine Susan P. et al	
	AC	US 5,124,342	6/23/1992	Kerdesky Francis A. J. et al.	
	AD	US,5,216,004	6/1/1993	Perrine Susan P.	
	AE	US 5,439,939	8/8/1995	Perrine Susan P.	
	AF	US 5,569,675	10/29/1996	Rephaeli Ada et al.	
	AG	US 5,645,852	7/8/1997	Newmark Harold L.	
	AH .	US 5,656,644	8/12/1997	Adams Jerry Leroy et al.	
	Al	US 5,700,826	12/23/1997	Mjalli Adnan et al.	
	AJ _	US 5,858,365	1/12/1999	Faller Douglas V	
	AK	US 5,922,837	7/13/1999	Meinke Peter T. et al.	
	AL	US 5,939,455	8/17/1999	Rephaeli Ada	
	AM	US 5,939,456 .	8/17/1999	Perine Susan P.	
	AN	US 5,993,845	11/30/1999	Geerts Albert Emmanuel Comeille et al.	
	AO	US 6,011,000	1/4/2000	Perrine Susan P. et al.	
	AP	US 6,030,961	2/29/2000	Nudelman Abraham et al.	
	AQ	US 6,040,342	3/21/2000	Rephaeli Ada et al.	
	AR	US 6,043,277	3/28/2000	Rephaeli Ada et al.	
1	AS	US 6,043,389	3/28/2000	Nudelman Abraham et al.	
	AT	US 6,068,987	5/30/2000	Dulski Paula M. et al.	
	AU	US 6,071,923	6/6/2000	Nudelman Abraham et al	
T	AV	US 6,110,697	8/29/2000	Dulski Paula M. et al.	
T	AW	US 6,110,955	8/29/2000	Nudelman Abraham et al.	
1	AX	US 6,110,970	8/29/2000	Nudelman Abraham et al.	
	AY	US 6,110,697	8/29/2000	Dulski Paula M. et al.	
	AZ	US 6,124,495	9/26/2000	Neiss Edward et al.	
	ВА	US 6,130,248	10/10/2000	Nudelman Abraham et al.	
	BB	US 6,174,905	1/16/2001	Suzuki Tsuneji et al.	
	BC	US 6,197,743	3/6/2001	Faller Douglas V.	
	BD	US 6,231,880	5/15/2001	Perrine Susan P.	
	BE	US 6,235,474	5/22/2001	Feinberg Andrew P.	
	BF	US 6,239,176	5/29/2001	Nudelman Abraham et al.	
	BG	US 6,262,116	7/17/2001	Pandolfi Pier Paolo et al.	

Examiner Signature	W	Date Considered	8/16/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitut	e for form 1449A/P	то		Complete if Known			
				Application Number	10/681,049		
INFO	PRMATION	N DIS	CLOSURE	Filing Date	October 07, 2003		
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Jerome C. Bressi		
				Group Art Unit	1621	·	
	(use as many si	heets as	necessary)	Examiner Name	Brian J. Davis		
Sheet	2	of	15	Attorney Docket Number	HDAC-5002-U		

ace	вн	US 2001/0009922A1	7/26/2001	Faller Douglas V.
1	BI	US 2001/0009922A1	8/9/2001	Hu Erding et al.
	BJ			Lelievre Sophie et al.
		US 6,287,790	9/11/2001	Perine Susan P. et al
	BK	US 2001/0027215A1	10/4/2001	
	BL	US 2001/0034367A1	10/25/2001	Faller Douglas V. et al.
	BM	US 6,329,402	12/11/2001	Kikuchi Kouichi et al.
	BN	US 6,335,170	1/1/2002	Omtoft Torben F.
	BO.	US 6,372,957	4/16/2002	Olson Eric N.
	BP	US 6,376,508	4/23/2002	Li Hung et al.
	BQ	US 6,387,673	5/14/2002	Evans Ronald M. et al.
	BR	US 2002/0061860A1	5/23/2002	Li Zuomei et al.
	BS	US 2002/0065282A1	5/30/2002	Georges Guy et al.
	BT	US 6,399,568	6/4/2002	Nishino Norikazu et al.
	BU .	US 6,403,555	6/11/2002	Skov S.
	BV	US 2002/0076457A1	6/20/2002	Aylward James Harrison
	BW	US 2002/0103192A1	8/1/2002	Curtin Michael L. et al.
	ВХ	US 6,428,983	8/6/2002	Dulski Paula M. et al.
	BY	US 2002/0107404A1	8/8/2002	Prien Olaf et al.
	BZ	US 2002/0115177A1	8/22/2002	Zhu Zimin
	CA	US 2002/0115826A1	8/22/2002	Delorme Daniel et al.
	CB	US 2002/0120099A1	8/29/2002	Nishino Norikazu et al.
	CC	US 2002/0119996A1	8/29/2002	Lan-Hargest Hsuan-Yin et al.
	CD	US 6,451,334	9/17/2002	Perrine Susan P. et al
	CE	US 2002/0132792A1	9/19/2002	Prien Olaf et al.
	CF	US 2002/0137162A1	9/26/2002	Li Zuomei et al.
	CG	US 2002/0137775A1	9/26/2002	Lan-Hargest Hsuan-Yin et al.
	СН	US 2002/0143037A1	10/3/2002	Lan-Hargest Hsuan-Yin et al.
	CI	US 2002/0143052A1	10/3/2002	Lan-Hargest Hsuan-Yin et al.
	3	US 2002/0143055A1	10/3/2002	Lan-Hargest Hsuan-Yin et al.
	СК	'US 2002/0143196A1	10/3/2002	Lan-Hargest Hsuan-Yin et al.
	CL	US 2002/0161045A1	10/31/2002	Lan-Hargest Hsuan-Yin et al.
	СМ	US 2002/0164752A1	11/7/2002	Meyers Rachel A.
	CN	US 6,479,629	11/12/2002	Baldwin Donald Adelphi et al.
	co	US 2002/0177594A1	11/28/2002	Curtin Michael L. et al.
	CP	US 2002/0183388A1	12/5/2002	Gudas Lorraine J.
	ca	US 2002/0183513A1	12/5/2002	Grossmann Adelbert et al.
	CR	US 6,495,719	12/17/2002	Lan-Hargest Hsuan-Yin et al.
-	CS	US 6,506,574	1/14/2003	Rambhatla Lakshmi et al.
		00 0,000,01 1	171-172000	

	· · · · · · · · · · · · · · · · · · ·		
Examiner	<i>L</i> /	Date	chila
Signature		Considered	8/16/06
3	L	1 00.100.00	<i>,</i> '

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in conformance and in considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitut	e for form 1449A/P	то		Complete if Known			
				Application Number	10/681,049		
INFO	PRMATIO	n dis	CLOSURE	Filing Date	October 07, 2003		
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Jerome C. Bressi		
				Group Art Unit	1621		
	(use as many s	sheets as	necessary)	Examiner Name	Brian J. Davis		
Sheet	3	of	15	Attorney Docket Number	HDAC-5002-U		

830	СТ	US 2003/0013176A1	1/16/2003	Pavletich Nikola et al.	
	CU	US 2003/0013757A1	1/16/2003	Leser-Reiff Ulrike et al.	
	CV	US 2003/0017454A1	1/23/2003	Sukumar Saraswati et al.	
	CW	US 2003/0018062A1	1/23/2003	Remiszewski Stacy W. et al.	
	СХ	US 6,512,123	1/28/2003	Grossmann Adelbert et al.	
	CY	US 6,511,990	1/28/2003	Breslow Ronald et al.	_
	CZ	US 6,518,012	2/11/2003	Tomasi Thomas B.	
	DA	US 6,531,472	3/11/2003	Georges Guy et al.	
\neg	DB	US 6,538,030	3/25/2003	Chung Yih-Lin et al.	
一	DC	US 2003/0059812A1	3/27/2003	Richon Victoria M. et al.	
\neg	DD	US 6,541,661	4/1/2003	Delorme Daniel et al.	
\neg	DE	US 6,544,957	4/8/2003 -	Kem Scott E. et al.	
\neg	DF	US 6,548,479	4/15/2003	Skov S.	
	DG	US 6,552,065	4/22/2003	Remiszewski Stacy William et al.	
	DH	US 2003/0078216A1	4/24/2003	MacLeod A. Robert et al.	
	DI	US 2003/0078369A1	4/24/2003	Meinke Peter T. et al.	
	Ŋ	US 2003/0082668A1	5/1/2003	Tamai Katsuyuki et al.	
	DK	US 2003/0082666A1	5/1/2003	Kammer Gary M. et al.	
	DL	US 2003/0083521A1	5/1/2003	Lan-Hargest Hsuan-Yin et al.	
	DM	US 6,562,995	5/13/2003	Lan-Hargest Hsuan-Yin et al.	
	DN	US 2003/0124101A1	7/3/2003	Gu Wei et al.	
	DO	US 2003/0125306A1	7/3/2003	Lan-Hargest Hsuan-Yin et al.	
	- DP	US 2003/0129724A1	7/10/2003	Grozinger Christina M. et al.	
	DQ	US 2003/0134865A1	7/17/2003	Adcock lan et al.	
	DR	US 2003/0139404A1	7/24/2003	Haag Rainer et al.	
\neg	DS	US 6,599,937	7/29/2003	Neiss Edward et al.	
	DT	US 2003/0143712A1	7/31/2003	Verdin Eric et al.	
	DU	US 2003/0144340A1	7/31/2003	Long Carlin et al.	
	DV	US 2003/0144276A1	7/31/2003	Kikuchi Kouichi et al.	
	DW	US 2003/0144340A1	7/31/2003	Long Carlin et al.	
7	DX	US 2003/0149261A1	8/7/2003	Schramm Vern L. et al.	
7	DY	US 2003/0148970A1	8/7/2003	Besterman Jeffrey M. et al.	
\neg	DZ	US 2003/0154032A1	8/14/2003	Pittman Debra D. et al.	
1	EA	US 2003/0152557A1	8/14/2003	Besterman Jeffrey M. et al.	
\top	EΒ	US 2003/0165956A1	9/4/2003	Stevens Craig W. et al.	
1	EC	US 2003/0165903A1	9/4/2003	Dang Van-Dinh et al.	
	ED	US 2003/0171409A1	9/11/2003	Lan-Hargest Hsuan-Yin et al.	

Examiner Signature	\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\	Date Considered	8/16/06	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional), 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitut	te for form 1449	A/PTO		Complete if Known			
				Application Number	10/681,049		
INFO	PRMATIC	on dis	CLOSURE	Filing Date	October 07, 2003		
STA	TEMEN'	T BY A	PPLICANT	First Named Inventor	Jerome C. Bressi		
				Group Art Unit	1621		
	(use as mar	ny sheets as	necessary)	Examiner Name	Brian J. Davis		
Sheet	4	of	15	Attorney Docket Number	HDAC-5002-U	_	

	EE	US 2003/0187027A1	10/2/2003	Schreiber Stuart L. et al.	
	EF	US 6,632,628	10/14/2003	Olson Eric N. et al.	
	EG	US 6,638,530	10/28/2003	Ishibashi Masahiko et al.	
	EH	US 2003/0207791A1	11/6/2003	Minucci Saverio et al.	
	EI	US 2003/0207325A1	11/6/2003	Guarente Leonard P. et al.	
	EJ	US 2003/0206946A1	11/6/2003	Chung Yih-Lin	
	EK	US 2003/0212121A1	11/13/2003	Kruger Martin et al.	
	EL	US 2003/0216345A1	11/20/2003	Nakanishi Osamu et al.	
	EM	US 2003/0219832A1	11/27/2003	Klein Elliott S. et al.	
	EN	US 6,656,905	12/2/2003	Mori Hiroaki et al.	
	EO	US 2003/0224473A1	12/4/2003	McCafferty Dewey G.	
	EP	US 2003/0224040A1	12/4/2003	Baylin Stephen B. et al.	
1	EQ	US 2003/0235873A1	12/25/2003	Krmer Joachim et al.	
	ER	US 2004/0002506A1	1/1/2004	Breslow Ronald et al.	
	ES	US 2004/0002447A1	1/1/2004	Levine Fred et al.	
	ET	US 2004/0002506A1	1/1/2004	Breslow Ronald et al.	
1	EU	US 6,673,587	1/6/2004	Evans Ronald M.	
	EV	US 2004/0005574A1	1/8/2004	Guarente Leonard et al.	
	EW	US 2004/0014647A1	1/22/2004	Lee Hyang Woo et al.	
	EX	US 2004/0018968A1	1/29/2004	Sgouros George et al.	:
	EY	US 2004/0018522A1	1/29/2004	Dangond Fernando et al.	
	ΕZ	US 2004/0024057A1	2/5/2004	Remiszewski Stacy William et al.	
	FA	US 2004/0023944A1	2/5/2004	Lan-Hargest Hsuan-Yin et al.	
	FB	US 6,689,558	2/10/2004	Case Casey	
	FC	US 2004/0028607A1	2/12/2004	Verdin Eric M. et al.	
	FD	US 2004/0029922A1	2/12/2004	Lan-Hargest Hsuan-Yin et al.	
	FE	US 2004/0029903A1	2/12/2004	Lan-Hargest Hsuan-Yin et al.	
	FF	US 6,699,902	3/2/2004	Lan-Hargest Hsuan-Yin et al.	
	FG	US 2004/0043470A1	3/4/2004	Xiao Yonghong	
	FH	US 6,706,762	3/16/2004	Evans Ronald M. et al.	
	FI	US 6,706,686	3/16/2004	Long Carlin et al.	
	FJ	US 2004/0053820A1	3/18/2004	Nakajima Hidenori et al.	
	FK	US 2004/0053960A1	3/18/2004	Georges Guy et al.	
	FL	US 2004/0058868A1	3/25/2004	James Stephen et al.	
	FM	US 6,720,445	4/13/2004	Lan-Hargest Hsuan-Yin et al.	
	FN	US 2004/0072735A1	4/15/2004	Richon Victoria M. et al.	
1	FO	US 2004/0072770A1	4/15/2004	Besterman Jeffrey M. et al.	

xamiņer ignature	4	Date Considered	8/16/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 144	9A/PTO		Complete if Known			
				Application Number	10/681,049		
INFO	PRMATI	ON DIS	CLOSURE	Filing Date	October 07, 2003		
STA	TEMEN	T BY A	PPLICANT	First Named Inventor	Jerome C. Bressi		
				Group Art Unit	1621		
	(use as ma	ny sheets as	necessary)	Examiner Name	Brian J. Davis		
Sheet	5	of	15	Attorney Docket Number	HDAC-5002-U		

NJO	FP	US 2004/0072849A1	4/15/2004	Schreiber Stuart L. et al.
1)	FQ	US 2004/0077578A1	4/22/2004	Monia Brett P. et al.
	FR	US 2004/0077084A1	4/22/2004	Watt Andrew T. et al.
	FS	US 2004/0077083A1	4/22/2004	Watt Andrew T.
	FT	US 2004/0077046A1	4/22/2004	Cohen Dalia et al.
	FU	US 2004/0077591A1		Dangond Femando
			4/22/2004	Watkins Clare J. et al.
	FV	US 2004/0077726A1	4/22/2004	Georges Guy et al.
	FW	US 2004/0077698A1	4/22/2004	Sidransky David
	FX	US 2004/0081976A1	4/29/2004	,
	FY	US 2004/0087657A1	5/6/2004	Richon Victoria M. et al.
	FZ	US 2004/0087652A1	5/6/2004	Gottlicher Martin et al.
	GA	US 2004/0087631A1	5/6/2004	Bacopoulos Nicholas G. et al.
	GB	US 2004/0091967A1	5/13/2004	Kohler Ranier H
	GC	US 2004/0091953A1	5/13/2004	Verdin Eric M. et al.
	GD	US 2004/0091951A1	5/13/2004	Schultz Brian E.
	GE	US 2004/0092558A1	5/13/2004	Klimko Peter G. et al.
	GF	US 2004/0092431A1	5/13/2004	Heliberg Peggy E.
	GG	US 2004/0092598A1	5/13/2004	Watkins Clare J. et al.
	GH	US 2004/0092572A1	5/13/2004	Renaud Johanne et al.
	GI	US 2004/0097439A9	5/20/2004	Nicolas Jean-Francois et al.
	GJ	US 2004/0102458A1	5/27/2004	Chiosis Gabriela et al.
	GK	US 2004/0106599A1	6/3/2004	Delorme Daniel et al.
	GL	US 2004/0122101A1	6/24/2004	Miller Thomas A. et al.
	GM	US 2004/0122079A1	6/24/2004	Grossmann Adelbert et al.
	GN	US 2004/0127571A1	7/1/2004	Bhalla Kapil N. et al.
	GO	US 2004/0127523A1	7/1/2004	Bacopoulos Nicholas G. et al.
	GP	US 2004/0127522A1	7/1/2004	Chiao Judy H. et al.
	GQ	US 2004/0138270A1	7/15/2004	George Fertig et al.
	GR	US 2004/0157930A1	8/12/2004	Mascagni Pacio et al.
	GS	US 2004/0157924A1	8/12/2004	Lan-Hargest Hsuan-Yin et al.
	GT	US 2004/0157841A1	8/12/2004	Fertig Georg et al.
	GU	US 6,777,217	8/17/2004	Schreiber Stuart L. et al.
	GV	US 2004/0161787A1	8/19/2004	Michnick Stephen William Watson et al.
	GW	US 2004/0162317A1	8/19/2004	Fertig Georg et al.
	GX	US 2004/0167184A1	8/26/2004	Wiech Norbert L. et al.
	GY	US 6,784,173	8/31/2004	Leser-Reiff Ulrike et al.
I	GZ	US 2004/0180962A1	9/16/2004	Truog Peter

Examiner	4/	Date	8/10/01
Signature		Considered	1/6/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial in reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and no considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitut	e for form 1449A	/PTO		Complete If Known		
				Application Number	10/681,049	
INFC	PMATIC	N DIS	CLOSURE	Filing Date	October 07, 2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	Jerome C. Bressi	
				Group Art Unit	1621	
	(use as many	sheets as	necessary)	Examiner Name	Brian J. Davis	
Sheet	6	of	15	Attorney Docket Number	HDAC-5002-U	

1500	НА	US 2004/0186274A1	9/23/2004	Allis C. David et al.	
1	НВ	US 2004/0186049A1	9/23/2004	Long Carlin et al.	
	НС	US 2004/0192744A1	9/30/2004	Haag Rainer et al.	
	HD	US 6,800,638	10/5/2004	Georges Guy et al.	
	HE	US 2004/0197888A1	10/7/2004	Christopher D. Amour et al.	
	HF	US 2004/0198830A1	10/7/2004	Watkins, Claire J. et al.	
	HG	US 2004/0204373A1	10/14/2004	Monia Brett P. et al.	
	НН	US 2004/0204339A1	10/14/2004	DiMartino Jorge F.	
	Н	US 6,809,118	10/26/2004	Chung Yih-Lin	
	HJ	US 2004/0213826A1	10/28/2004	Marx Steven O. et al.	
	нк	US 2004/0214880A1	10/28/2004	Fertig Georg et al.	
	HL	US 2004/0214862A1	10/28/2004	Leser-Reiff Ulrike et al.	
	НМ	US 2004/0224991A1	11/11/2004	Lu Xian-Ping et al.	
	HN	US 2004/0229889A1	11/18/2004	Urano Yasuharu et al.	
	но	US 6,825,317	11/30/2004	Nishino Norikazu et al.	
	HP	US 6,828,302	12/7/2004	Skov S.	
	HQ	US 6,831,061	12/14/2004	Lee Hyang Woo et al.	
	HR	US 2004/0254220A1	12/16/2004	Bressi Jerome C. et al.	
	нѕ	US 6,833,384	12/21/2004	Remiszewski Stacy William et al.	
	HT	US 2004/0259772A1	12/23/2004	Fojo Antonio et al.	
	HU	US 2004/0266718A1	12/30/2004	Li Zuomei et al.	
	HV	US 2004/0266818A1	12/30/2004	Breslow Ronald et al.	
	HW	US 2004/0266769A1	12/30/2004	Bressi Jerome C. et al.	•
	НХ	US 2005/0003031A1	1/6/2005	Aylward James Harrison	
	HY	US 6,841,565	1/11/2005	Lucas David M. et al.	
	HZ	US 2005/0009030A1	1/13/2005	Schweighoffer Fabien et al.	
	IA	US 2005/0020557A1	1/27/2005	Johnson Robert JR, et al.	
	IB	US 2005/0026907A1	2/3/2005	Wash Paul L. et al.	
	IC	US 2005/0032899A1	2/10/2005	Chen Ying-Nan Pan et al.	
	ID	US 2005/0032831A1	2/10/2005	Kozikowski Alan P. et al.	
	IE	US 2005/0032794A1	2/10/2005	Padia Janak K. et al.	
	IF	US 2005/0038113A1	2/17/2005	Groner Bernd et al.	
	IG	US 2005/0037992A1	2/17/2005	Lyons John et al.	
	IH	US 2005/0059682A1	3/17/2005	Rubinfeld Joseph	
	Н	US 6,869,953	3/22/2005	Haag Rainer et al.	
	IJ	US 2005/0065596A1	3/24/2005	Tseng Xufan et al.	
	IK	US 2005/0070467A1	3/31/2005	Nace Yoshinori	

Examiner	1	Date	8/11/01
Signature		Considered	0/14/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449	AVPTO			Complete if Known
				Application Number	10/681,049
INFC	PMATI	on dis	CLOSURE	Filing Date	October 07, 2003
STA	STATEMENT BY APPLICANT			First Named Inventor	Jerome C. Bressi
				Group Art Unit	1621
	(use as many sheets as necessary)			Examiner Name	Brian J. Davis
Sheet	7	of	15	Attorney Docket Number	HDAC-5002-U

830	IL	US 6,875,598	4/5/2005	Buggy Joseph
	IM	US 2005/0080249A1	4/14/2005	Buggy Joseph
	IN	US 2005/0079995A1	4/14/2005	Bedaloy Antonio et al.
	10	US 2005/0085515A1	4/21/2005	Watkins Clare J. et al.
	IP	US 2005/0084967A1	4/21/2005	Berenson Ronald J. et al.
	IQ	US 2005/0085507A1	4/21/2005	Remiszewski Stacy William et al.
	IR	US 2005/0085515A1	4/21/2005	Watkins Clare J. et al.
	IS	US 6,884,597	4/26/2005	Taya Yoichi et al.
	IT	US 6,888,027	5/3/2005	Watkins Clare J. et al.
	īU	US 2005/0096468A1	5/5/2005	Van Emelen Kristof et al.
	IV	US 2005/0107445A1	5/19/2005	Watkins Clare J. et al.
	IW	US 2005/0106654A1	5/19/2005	Olson Eric N. et al.
	IX	US 2005/0107445A1	5/19/2005	Watkins Clare J. et al.
	IY	US 2005/0107384A1	5/19/2005 .	Angibaud Patrick Rene et al.
	ΙZ	US 2005/0107348A1	5/19/2005	Lan-Hargest Hsuan-Yin et al.
	JA	US 6,897,220	5/24/2005	Delome Daniel et al.
	JB	US 2005/0113373A1	5/26/2005	Van Emelen Kristof et al.
	JC	US 2005/0118596A1	6/2/2005	Asselbergs Fredericus Alphonsus Maria et al.
	JD	US 2005/0119250A1	6/2/2005	Angibaud Patrick Rene et al.
	JE	US 2005/0124679A1	6/9/2005	Kim Dae-Kee et al.
	JF	US 6,905,669	6/14/2005	DiMartino Jorge F.
	JG	US 2005/0130146A1	6/16/2005	Zelent Arthur et al.
	JH	US 2005/0131018A1	6/16/2005	Sendzik Martin et al.
	JI	US 2005/0137234A1	6/23/2005	Bressi Jerome C. et al.
	JJ	US 2005/0137232A1	6/23/2005	Bressi Jerome C. et al.
	JK	US 2005/0136090A1	6/23/2005	Falotico Robert et al.
	JL	US 2005/0143385A1	6/30/2005	Watkins Clare J. et al.
.] -	JM	US 2005/0148613A1	7/7/2005	Van Emelen Kristof et al.
	JN	US 2005/0159347A1	7/21/2005	DiMartino Jorge F.
	JO	US 2005/0159470A1	7/21/2005	Bressi Jerome C. et al.
	JP	US 2005/0165016A1	7/28/2005	Van Emelen Kristof
	JQ	US 2005/0171042A1	8/4/2005	Monia Brett P. et al.
	JR	US 2005/0171027A1	8/4/2005	Sindair David A. et al.
	JS	US 2005/0171347A1	8/4/2005	Emelen Kristof Van et al.
	JT	US 2005/0171208A1	8/4/2005	Lan-Hargest Hsuan-Yin et al.
	JU	US 2005/0171103A1	8/4/2005	Stokes Elaine Sophie Elizabeth et al.

Examiner Signature	4	. Date Considered	8/14/06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
	Application Number	10/681,049 ·			
INFORMATION DISCLOSU	RE Filling Date	October 07, 2003			
STATEMENT BY APPLICA	NT First Named Inventor	Jerome C. Bressi			
	Group Art Unit	1621			
(use as many sheets as necessary)	Examiner Name	Brian J. Davis			
Sheet 8 of 15	Attorney Docket Number	HDAC-5002-U			

830	JV	US 2005/0176764A1	8/11/2005	Mataki Chikage et al.	
	JW	US 2005/0176686A1	8/11/2005	Maurer Alexander B. et al.	
	JX	US 2005/0187261A1	8/25/2005	Verner Erik J. et al.	
L	JY	US 2005/0191713A1	9/1/2005	Sasakawa Yuka et al.	

·	FOREIGN PATENT DOCUMENTS						
		Foreign Patent Document			Pages, Columns, Lines, Where		
Examiner Initials*	Cite No. ¹	Country Code ³ – Number ⁴ – Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	T ⁰	
BOD	JZ	WO 96/15096 A1	5/23/1996	BAYER CORPORATION			
1	KA	WO 97/02244 A1	1/23/1997	EISAI CO., LTD.,			
	КВ	WO 97/11366 A1	3/27/1997	MERCK & CO., INC.			
	КС	WO 97/35990 A2 & A3	10/2/1997	PRESIDENT AND FELLOWS OF HARVARD COLLEGE			
	KD	WO 97/47307 A1	12/18/1997	UAB RESEARCH FOUNDATION			
	KE	WO 98/00127 A1	1/8/1998	REPHAELI, Ada			
	KF	WO 98/28269 A1	7/2/1998	THE DUPONT MERCK PHARMACEUTICAL COMPANY			
	KG	WO 98/29114 A1	7/9/1998	BEACON LABORATORIES L.L.C.			
	KH	WO 98/39966 A1	9/17/1998	BEACON LABORATORIES, L.L.C.			
	KI	WO 98/40065 A1	9/17/1998	BEACON LABORATORIES, L.L.C.			
	KJ	WO 98/40080 A1	9/17/1998	MOR RESEARCH APPLICATIONS, LTD.			
	KK	WO 98/48825 A1	11/05/1998	SALK INSTITUTE FOR BIOLOGICAL STUDIES			
	KL	WO 98/55449 A1	12/10/1998	QUEENSLAND INSTITUTE OF MEDICAL RESEARCH			
	KM	WO 99/11659 A1	3/11/1999	JAPAN ENERGY CORPORATION			
	KN	WO 99/23885 A1	5/20/1999	SALK INSTITUTE FOR BIOLOGICAL STUDIES			
	ко	WO 99/37150 A1	7/29/1999	SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH			
	KP	WO 99/61413 A1	12/2/1999	BAYER CORPORATION			
	KQ	WO 00/08048 A2 & A3	2/17/2000	FWISAWA PHARMACEUTICAL CO., LTD.			
	KR	WO 00/010583 A1	3/2/2000	SMITHKLINE BEECHAM CORPORATION			

Signature Considered //2/00	Examiner Signature	Date Considered	8/14/06
-----------------------------	-----------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449	PA/PTO		Complete if Known		
			·	Application Number	10/681,049	
INFORMATION DISCLOSURE				Filing Date	October 07, 2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	Jerome C. Bressi	
				Group Art Unit	1621	
	(use as mai	ny sheets as	necessary)	Examiner Name	Brian J. Davis	
Sheet	9	of	15	Attorney Docket Number	HDAC-5002-U	フ

poo	KS	WO 00/021979 A2 & A3	4/20/2000	FWISAWA PHARMACEUTICAL CO., LTD.	
	кт	WO 00/023567 A2 & A3	4/27/2000	NOVARTIS AG	
	KU	WO 00/52033 A1	9/8/2000	JAPAN ENERGY CORPORATION	
	ΚV	WO 00/56917 A1	9/28/2000	CHUGAI RESEARCH INSTITUTE FOR MOLECULAR MEDICINE, INC.	
	кw	WO 00/118045 A1	10/8/2000	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	
	кх	WO 00/61576 A1	10/19/2000	SMITHKLINE BEECHAM CORPORATION	
	KY	WO 00/71703 A2 & A3	11/30/2000	METHYLGENE INC.	
	KZ	WO 01/07042 A1	2/1/2001	MERCK & CO., INC.	
[_	LA	WO 01/14581 A3	3/1/2001	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	•
	LB	WO 01/16106 A1	3/8/2001	SCHERING AKTIENGESELLSCHAFT	·
	ГС	WO 01/17514 A1	3/15/2001	SALK INSTITUTE OF BIOLOGICAL STUDIES	
	ΓD	WO 01/018045 A1	3/15/2001	TRUSTEES OF COLUMBIA UNIVERSITY IN CITY OF NEW YORK	
	LE	WO 01/18171 A2 & A3	3/15/2001	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	
	LF	WO 01/27314 A1	4/19/2001	MERCK & CO., INC.	
	LĠ	WO 01/38322 A1	5/31/2001	METHYLGENE, INC.	
	LH	WO 01/42437 A2 & A3	6/14/2001	AXYS PHARMACEUTICALS, INC.	
	LI	WO 01/67107 A1	9/13/2001	IMPERIAL COLLEGE INNOVATIONS LIMITED	
	IJ	WO 01/70675 A3	9/27/2001	METHYLGENE, INC.	
	LK	WO 01/72784 A2 & A3	10/4/2001	FILGEN BIOSCIENCES, INC.	
	LL	WO 01/72737 A1	10/4/2001	SMITHKLINE BEECHAM CORPORATION	
	LM	WO 02/06307 A1	1/24/2002	FWISAWA PHARMACEUTICAL CO., LTD.	
	LN	WO 02/08273 A2 & A3	1/31/2002	MILLENNIUM PHARMACEUTICALS, INC.	
	LO	WO 02/07722 A2 & A3	1/31/2002	GEORG-SPEYER-HAUS	
	LP	WO 02/15921 A2 & A3	2/28/2002	GOVERNEMENT OF UNITED STATES OF AMERICA, represented by SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	•
	LQ	WO 02/22133 A1	3/21/2002	VIRGINIA COMMONWEALTH UNIVERSITY	
	LR	WO 02/22577 A3	3/21/2002	NOVARTIS AG .	
	LS	WO 02/26696 A1	4/4/2002	PROLIFIX LIMITED	

Examiner	, /	Date	a leader
Signature	7 /	Considered	8/16/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

HDAC-5002-U

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number

10/681,049

Filing Date
October 07, 2003

First Named Inventor
Group Art Unit
1621

Examiner Name
Brian J. Davis

Attorney Docket Number

Sheet

10

of

15

836	LT	WO 02/26703 A1	4/4/2002	PROLIFIX LIMITED	
1	LU	WO 02/30879 A2 & A3	4/18/2002	PROLIFIX LIMITED	
-	LV	WO 02/30970 A2 & A3	4/18/2002	BAYER AKTIENGESELLSCHAFT	
	LW	WO 02/36783 A2 & A3	5/10/2002	BAYER AKTIENGESELLSCHAFT	
	LX	WO 02/36075 A2 & A3	5/10/2002	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	
	LY	WO 02/46144 A1	6/13/2002	F. HOFFMANN-LA ROCHE AG	
	LZ	WO 02/46129 A2 & A3	6/13/2002	ABBOTT LABORATORIES	
	MA	WO 02/50244 A3	6/27/2002	ISIS PHARMACEUTICALS, INC.	
	MB	WO/0250285 A2 & A3	6/27/2002	NOVARTIS AG	
	MC	WO 02/051842 A1	7/4/2002	F. HOFFMANN-LA ROCHE AG	
	MD	WO 02/055017 A3	7/18/2002	WAKE FOREST UNIVERSITY	
	ME	WO 02/055688 A2 & A3	7/18/2002	GOVERNMENT OF UNITED STATES OF AMERICA, as represented by SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES	
	MF	WO 02/060430 A1	8/8/2002	CORNELL RESEARCH FOUNDATION, INC.	
	MG	WO 02/062773 A1	8/15/2002	F. HOFFMANN-LA ROCHE AG	
	MH	WO 02/069947 A2 & A3	9/12/2002	METHYLGENE, INC.	
	MI	WO 2002/076941 A2 & A3	10/3/2002	CIRCAGEN PHARMACEUTICAL	
	MJ	WO 02/083173 A1	10/24/2002	DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS	
	MK	WO 02/085400 A1	10/31/2002	SUPERGEN, INC.	
	ML	WO 02/085883 A1	10/31/2002	F. HOFFMANN-LA ROCHE AG	
	ММ	WO 02/089782 A2 & A3	11/14/2002	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	
	MN	WO 02090534 A1	11/14/2002	REGENTS OF UNIVERSITY OF CALIFORNIA	
	МО	WO 02/102316 A2 & A3	12/27/2002	REGENTS OF THE UNIVERSITY OF CALIFORNIA	
	MP	WO 02/102323 A2	12/27/2002	BRISTOL-MYERS SQUIBB COMPANY	
	MQ	WO 02/102984 A2 & A3	12/27/2002	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	
	MR	WO 03/000715 A1	1/3/2003	CERES, INC.	
	MS	WO 2003/006652 A2 & A3	1/23/2003	METHYLGENE, INC.	
	MT	WO 03/011851 A3	2/13/2003	F. HOFFMAN-LA ROCHE AG	
	MU	WO 03/013493 A1	2/20/2003	ITALFARMACO S.P.A.	
1	MV	WO 03/014340 A2 & A3	2/20/2003	NOVARTIS AG	

	Examiner Signature	2	Date Considered 8/10/01	
--	-----------------------	---	-------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

HDAC-5002-U

Substitute for form 1449A/PTO Complete if Known 10/681,049 **Application Number** INFORMATION DISCLOSURE Filing Date October 07, 2003 STATEMENT BY APPLICANT Jerome C. Bressi First Named Inventor **Group Art Unit** 1621 (use as many sheets as necessary) **Examiner Name** Brian J. Davis

Attomey Docket Number

Sheet

11

of 15

ls:	Ø	MW	WO 03/015810 A1	2/27/2003	FWISAWA PHARMACEUTICAL CO., LTD.
	. 7	MX	WO 03/024442 A2 & A3	3/27/2003	G2M CANCER DRUGS AG
		MY	WO 03/024448 A2 & A3	3/27/2003	METHYLGENE, INC.
		MZ	WO 03/029451 A2 & A3	4/10/2003	INSTITUTE OF CANCER RESEARCH
		NA	WO 03/032921 A2 & A3	4/24/2003	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
ŀ	•	NB	WO 03/033678 A3	4/24/2003	SALK INSTITUTE FOR BIOLOGICAL STUDIES
		NC	WO 03/039599 A1	5/15/2003	NOVARTIS AG
		ND	WO 03/046207 A2	6/5/2003	FRED HUTCHINSON CANCER RESEARCH CENTER
		NE	WO 03/048774 A1	6/12/2003	NOVARTIS AG
		NF	WO 03/053468 A1	7/3/2003	UNIVERSITE LIBRE DE BRUXELLES
		NG	WO 03/057722 A2 & A3	7/17/2003	FWISAWA PHARMACEUTICAL CO., LTD.
		NH	WO 03/059864 A2 & A3	7/24/2003	SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
		NI	WO 03/066579 A2 & A3 .	8/14/2003	AXYS PHARMACEUTICALS
		N	WO 03/066885 A2 & A3	8/14/2003	NOVARTIS AG
		NK	WO 03/066889 A2 & A3	8/14/2003	AXYS PHARMACEUTICALS, INC.
		NL	WO 2003/070188 A2 & A3	8/28/2003	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
		NM	WO 03/070691 A1	8/28/2003	OSAKA INDUSTRIAL PROMOTION ORGANIZATION
		NN	WO 03/070754 A1	8/28/2003	HORINOUCHI, Sueharu
	L	NO	WO 2003/075839 A2 & A3	9/18/2003	ATON PHARMA, INC.
		NP	WO 03/075929 A1	9/18/2003	JANSSEN PHARMACEUTICA N.V.
		NQ	WO 03/076395 A1	9/18/2003	JANSSEN PHARMACEUTICA N.V.
		NR	WO 03/076400 A1	9/18/2003	JANSSEN PHARMACEUTICA N.V.
		NS	WO 03/076401 A1	9/18/2003	JANSSEN PHARMACEUTICA N.V.
	Ш	NT	WO 03/076421 A1	9/18/2003	JANSSEN PHARMACEUTICA N.V.
L	Ш	NU	WO 03/076422 A1	9/18/2003	JANSSEN PHARMACEUTICA N.V.
	Ш	NV	WO 03/076430 A1	9/18/2003	JANSSEN PHARMACEUTICA N.V.
		NW	WO 03/076438 A1	9/18/2003	JANSSEN PHARMACEUTICA N.V.
	Щ	NX	WO 03/080864 A1	10/2/2003	EXHONIT THERAPEUTICS SA
	Ш	NY	WO 03/082288 A1	10/9/2003	PROLIFIX LIMITED
	L	NZ	WO 03/083067 A2	10/9/2003	BRIGHAM AND WOMEN'S HOSPITAL, INC.

Signature Considered 6/16/01	Examiner Signature	/ /	Date Considered	8/16/06
------------------------------	-----------------------	------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
INFORMATION DISCLOSURE				Application Number	10/681,049	
				Filing Date	October 07, 2003	
STATEMENT BY APPLICANT		First Named Inventor	Jerome C. Bressi			
				Group Art Unit	1621	
	(use as many sheets as necessary)			Examiner Name	Brian J. Davis	
Sheet	12	of	15	Attorney Docket Number	HDAC-5002-U	

	OA	WO 03/084611 A1	10/16/2003	GOVERNMENT OF UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES		
BDO	ОВ	WO 03/086397 A1	10/23/2003	KOWA CO., LTD.		
	ОС	WO 03/087057 A1	10/23/2003	ASTRAZENECA AB		
	OD	WO 03/087066 A1	10/23/2003	IN2GEN CO., LTD.		
	OE	WO 03/088954 A1	10/30/2003	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH		
	OF	WO 03/092686 A1	11/13/2003	ASTRAZENECA AB		
	OG	WO 03/099210 A3	12/4/2003	REGENTS OF UNIVERSITY OF CALIFORNIA		
	ОН	WO 03/099272 A1	12/4/2003	BEACON LABORATORIES, INC.		
	OI	WO 03/099760 A1	12/4/2003	BEACON LABORATORIES, INC		
	Q	WO 03/099789 A1	12/4/2003	BEACON LABORATORIES, INC.		
	ОК	WO 03/100089 A1	12/4/2003	REGENTS OF UNIVERSITY OF CALIFORNIA		
	OL	WO 2003/103613 A2 & A3	12/18/2003	REGENTS OF UNIVERSITY OF CALIFORNIA		
	ОМ	WO 03/103712 A1	12/18/2003	NOVARTIS AG		
	ON	WO 2004/001072 A2	12/31/2003	JAPAN AS REPRESENTED BY THE PRESIDENT OF THE UNIVERSITY OF TOKYO		
	00	WO 04/002944 A1	1/8/2004	PHARMACIA & UPJOHN COMPANY		
	OP	WO 2004/005282 A1	1/15/2004	NOVARTIS AG		
	OQ	WO 2004/005513 A2	1/15/2004	METHYLGENE, INC.		
	OR	WO 2004/006909 A1	1/22/2004	TITAN PHARMACEUTICALS, INC.		
	os	WO 2004/009092 A1	1/29/2004	CHEMGENEX THERAPEUTICS, INC.		
	ОТ	WO 2004/009536 A1	1/29/2004	G2M CANCER DRUGS AG		
	ΟU	WO 2004/009771 A2	1/29/2004	ADVANCED STENT TECHNOLOGIES, INC.	_	
	OV	WO 2004/013130 A1	2/12/2004	ARGENTA DISCOVERY LIMITED		
	ow	WO 04/017996 A1	3/4/2004	YAMANOUCHI PHARMACEUTICAL CO., LTD.		
	ОХ	WO 2004/020460 A1	3/11/2004	YAMANOUCHI PHARMACEUTICAL CO., LTD.		
	OY	WO 2004/024160 A1	3/25/2004	MCGUIRE VA MEDICAL CENTER 111K		
	OZ	WO 2004/026234 A2	4/1/2004	UNIVERSITY OF SOUTH FLORIDA		
	PA	WO 2004/027418 A3	4/1/2004	FORSCHUNGSZENTRUM KARLSRUHE GMBH		
L	PB	WO 2004/029622 A2	4/8/2004	G2M CANCER DRUGS AG		

Examiner Signature	W	Date Considered	8/14/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO					Complete if Known		
•				Application Number	10/681,049		
INFO	PRMATI	on dis	CLOSURE	Filing Date	October 07, 2003		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Jerome C. Bressi		
				Group Art Unit	1621		
	(use as many sheets as necessary)			Examiner Name	Brian J. Davis		
Sheet	13	of	15	Attorney Docket Number	HDAC-5002-U		

836	PC	WO 2004/031388 A1	4/15/2004	SONY CORPORATION	
	PD	WO 2004/035525 A1	4/29/2004	METHYLGENE INC.	
	PE	WO 2004043352 A2	5/27/2004		
	PF	WO 2004/043348 A2	5/27/2004	ALCON, INC.	
	PG	WO 2004/046094 A1	6/3/2004	BARTS AND THE LONDON NHS TRUST	
	PH	WO 2004/046104 A2	6/3/2004	CIRCAGEN PHARMACEUTICAL	
	Pi	WO 2004/046312 A2	6/3/2004	BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS	
	PJ	WO 04/052292 A2	6/24/2004	UNIVERSITY OF SOUTH FLORIDA,	
	PK	WO 04/052838 A1	6/24/2004	F. HOFFMANN-LA ROCHE AG	
	PL	WO 04/053140 A2	6/24/2004	JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH	
	РМ	WO 04/054999 A1	7/1/2004	F. HOFFMANN-LA ROCHE AG	
	PN	WO 04/056877 A1	7/8/2004	SINTOFARM S.P.A.,	
	PO	WO 04/063146 A1	7/29/2004	ITALFARMACO SPA	
	PP	WO 04/063169 A1	7/29/2004	FUJISAWA PHARMACEUTICAL CO.	
l	PQ	WO 04/064727 A2	8/5/2004	GEORGETOWN UNIVERSITY	
	PR	WO 04/065354 A1	8/5/2004	TOPOTARGET UK LIMITED	
	PS	WO 04/067480 A2	8/12/2004	OXFORD GLYCOSCIENCES (UK) LTD	
1	PT	WO 2004/069133 A2	8/19/2004	F. HOFFMANN-LA ROCHE AG	
	PU	WO 2004/069803 A2	8/19/2004	F. HOFFMANN-LA ROCHE AG	
	PV	WO 2004/069823 A1	8/19/2004	METHYLGENE, INC.	
	PW	WO 2004/070351 A2	8/19/2004	ODYSSEY THERA, INC.	
	PX	WO 2004/071400 A2	8/26/2004	SHENZHEN CHIPSCREEN BIOSCIENCES LTD.	
	PY	WO 2004/071401 A2	8/26/2004	FWISAWA PHARMACEUTICAL CO., LTD.	
	PZ	WO 2004/071443 A2	8/26/2004	IRM LLC	
	QA	WO 2004/071464 A2	8/26/2004	JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE	
	QB	WO 2004/072047 A1	8/26/2004	FWISAWA PHARMACEUTICAL CO., LTD.	
	QC	WO 2004/072265 A2	8/26/2004	WYETH	ļ
	QD	WO 2004/074478 A1	9/2/2004	FWISAWA PHARMACEUTICAL CO., LTD.	
	QE	WO 04/076386 A2	9/10/2004	TOPOTARGET UK LIMITED	
	QF	WO 04/082638 A2	9/30/2004	SYRRX, INC.,	
\vdash	QG	WO 2004/089293 A2	10/21/2004	TRUSTEES OF COLUMBIA UNIVERSITY IN CITY OF NEW YORK	

Examiner Signature	\mathcal{N}	Date Considered	8/16/00	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitut	e for form 1449A/PT	ro		Complete if Known		
				Application Number	10/681,049	
INFORMATION DISCLOSURE				Filing Date	October 07, 2003	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Jerome C. Bressi	
				Group Art Unit	1621	
	(use as many sheets as necessary)			Examiner Name	Brian J. Davis	
Sheet	14	of	15	Attorney Docket Number	HDAC-5002-U	

BOO	QH	WO 2004/092115 A2	10/28/2004	AXYS PHARMACEUTICALS INC.	
	QI	WO 2004/098495 A2	11/18/2004	TRUSTEES OF COLUMBIA UNIVERSITY IN CITY OF NEW YORK	
	ΟΊ	WO 04/103358 A2	12/2/2004	NOVARTIS AG	
	QK	WO 04/103369 A1	12/2/2004	SCHERING AKTIENGESELLSCHAFT	
	QL	WO 04/110418 A2	12/23/2004	KALYPSYS, INC.	
	QM	WO 04/112763 A2	12/29/2004	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS	
	QN	WO 04/113336 A1	12/29/2004	CHROMA THERAPEUTICS LIMITED	
	QO	WO 2005/000213 A2	1/6/2005	KOSAN BIOSCIENCES, INC.	
	QP	WO 2005/000282 A2	1/6/2005	G2M CANCER DRUGS AG	
	QQ	WO 2005/000289 A1	1/6/2005	G2M CANCER DRUGS AG	
	QR	WO 2005/000332 A2	1/6/2005	FWISAWA PHARMACEUTICAL CO., LTD.	
	QS .	WO 05/002555 A2	1/13/2005	PRESIDENT AND FELLOWS OF HARVARD COLLEGE,	
	QT	WO 05/002672 A2	1/13/2005	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	
	QU	WO 05/004861 A1	1/20/2005	KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY	
	QV	WO 2005/007091 A2	1/27/2005	GEORGETOWN UNIVERSITY	
	QW	WO 2005/007158 A1	1/27/2005	OHIO STATE UNIVERSITY RESEARCH FOUNDATION	
	QΧ	WO 2005/009349 A2	2/3/2005	SUPERGEN, INC.	
	QY	WO 05/011598 A2	2/10/2005	UNIVERSITY OF SOUTH FLORIDA	
	QZ	WO 05/011661 A1	2/10/2005	UNIVERSITY COLLEGE LONDON	
	RA	WO 05/013958 A1	2/17/2005	NOVARTIS AG	
	RB	WO 05/014004 A1	2/17/2005	NOVARTIS AG	
	RC	WO 05/014588 A1	2/17/2005	ARGENTA DISCOVERY LIMITED	1
	RD	WO 05/016264 A2	2/24/2005	AVALON PHARMACEUTICALS,	
	RE	WO 2005/016342 A1	2/24/2005	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	
	RF	WO 05/018578 A2	3/3/2005	ATON PHARMA, INC.	
	RG	WO 05/019174 A1	3/3/2005	AXYS PHARMACEUTICALS, INC.,	
	RH	WO 05/023179 A2	3/17/2005	ATON PHARMA, INC.	
	RI	WO 05/025619 A1	3/24/2005	NOVARTIS AG	
7 1	RJ	WO 05/028447 A1	3/31/2005	S'BIO PTE LTD	
エ	RK	WO 05/028620 A2	3/31/2005	ROCKEFELLER UNIVERSITY	

	, _ , _ , _ , _ , , , , , ,		
Examiner Signature	4	Date Considered	8/16/0C
9191141141		1 00110100100	· · · //

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

BODRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitut	e for form 1449A/P	то		Complete if Known		
				Application Number	10/681,049	
INFO	PRMATIO	n dis	CLOSURE	Filing Date	October 07, 2003	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Jerome C. Bressi	
	•		- -	Group Art Unit	1621	_
(use as many sheets as necessary)				Examiner Name	Brian J. Davis	
Sheet	15	of	15	Attorney Docket Number	HDAC-5002-U	

aco	RL	WO 05/030704 A1	4/7/2005	METHYLGENE, INC.	
1	RM	WO 05/030705 A1	4/7/2005	METHYLGENE, INC.	
\top	RN	WO 05/034880 A2	4/21/2005	ATON PHARMA, INC.	
	RO	WO 2005/039498 A2	5/6/2005	ATON PHARMA, INC.	
	RP	WO 2005/040101 A1	5/6/2005	S'BIO PTE LTD	
	RQ	WO 2005/040136 A1	5/6/2005	BRISTOL-MYERS SQUIBB COMPANY	
	RR	WO 2005/040161 A1	5/6/2005	S'BIO PTE LTD	
	RS	WO 05/047457 A2	5/26/2005	JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH	
	RT	WO 05/051901 A1	6/9/2005	UNIVERSITY OF QUEENSLAND	
	RU	WO 2005/053609 A2	6/16/2005	GUILFORD PHARMACEUTICALS INC.	
	RV	WO 2005/053610 A2	6/16/2005	ATON PHARMA, INC.	
	RW	WO 05/055928 A2 & A3	6/23/2005	OHIO STATE UNIVERSITY RESEARCH FOUNDATION	
	RX .	WO 05/058298 A2	6/30/2005	WISCONSIN ALUMNI RESEARCH FOUNDATION	
	RY	WO 05/058803 A1	6/30/2005	EXONHIT THERAPEUTICS SA	
1	RZ	WO 2005/065681 A1	7/21/2005	SYRRX, INC.	
I	SA	WO 2005/066151 A2	7/21/2005	SYRRX, INC.	
L	SB	WO 05/071079 A1	8/4/2005	ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA	

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				

Examiner Signature	4	Date Considered	8/11/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.